News

The future of cardiac PET

07
Dec

CPT categorization and Coronary Flow Reserve

The American Medical Association has proposed a CPT code for Absolute quantitation of myocardial blood flow with PET (0482T) effective 1/1/2018. See link below:

 

https://www.ama-assn.org/sites/default/files/media-browser/public/cpt/cpt-category3-codes-descriptors.pdf

 

 

Print this page

01
Mar

A recent article suggest that PET may be more accurate for diagnosing coronary artery disease the SPECT or CTA. Link below: 

https://www.tctmd.com/news/pet-more-accurate-diagnosing-cad-spect-and-ct-angiography-pacific-study

Print this page

08
Mar

The American College of Radiology (ACR), together with over 300 stakeholder organizations in the Ad Hoc Group for Medical Research, helped to realize research funding goals in the new $1.3 trillion federal budget bill passed by Congress March 22 and signed one day later by President Donald Trump.

 

Full Text

Print this page

30
Mar

The American Society of Nuclear Cardiology (ASNC) has published an updated consensus statement on evidence-based treatment of stress myocardial perfusion imaging (MPI) in women. The consensus statement, “Myocardial perfusion imaging in women for the evaluation of stable ischemic heart disease—state-of-the-art evidence and clinical recommendations,” is intended to guide appropriate use of nuclear cardiology in the evaluation of women presenting with symptoms consistent with stable ischemic heart disease (SIHD).

Full Article

Print this page

03
Apr

The Society of Nuclear Medicine and Molecular Imaging’s (SNMMI) Cardiovascular Council and the American Society of Nuclear Cardiology (ASNC) have issued the joint position paper, Clinical Quantification of Myocardial Blood Flow Using PET, which was jointly published in the Journal of Nuclear Cardiology and The Journal of Nuclear Medicine.

 

Full Text

Print this page

02
Aug

POSITRON APPOINTS NEW MANAGEMENT

ADEL ABDULLAH PRESIDENT & AARON HARGRAVE VICE PRESIDENT

 

Niagara Falls, NY –August 2, 2018– Positron Corporation (OTC:POSC)(the “Company”), a nuclear medicine healthcare company, announces the appointment of Adel Abdullah  as its President. Mr. Abdullah will also serve as a Director of the Board. Mr. Abdullah will lead the Company in its strategic plan and long term objectives moving forward.  Adel Abdullah has been instrumental to Positron’s ability to deliver world class PET imaging technology, clinical & technical services to customers for over 10 years and will continue to do so for Positron’s customers.  

 

Positron is also pleased to announce the appointment of Aaron Hargrave, Positron’s Director of Clinical Applications as Vice President.  Mr. Hargrave is a Certified Nuclear Medicine Technologist, performing PET imaging in cardiac, oncology and neurologic subsets for Positron since 2010. Mr. Hargrave provides clinical and software support and training for Positron’s Attrius PET customers specializing in image quality and interpreting technical data, ensuring proper product use for optimal patient outcomes.

 

Mr. Abdullah and Mr. Hargrave have delivered top performing PET technology used in over 50,000 cardiac studies on Positron imaging systems. 

                                                                                                                    

Mr. Abdullah stated, “It is an exciting time at Positron. As a company we are on a new path that I expect will have great impact in the growth of the cardiac PET industry. Positron is stronger than ever with the ability to focus exclusively on its imaging technology, clinical services and innovative pro-business structures for its customers. Our goal is to work with champions of the cardiac PET industry to advance the adoption of cardiac PET utilizing Positron’s PET imaging systems and services.    

 

About Positron: Positron Corporation is a nuclear medicine healthcare company providing innovative PET technologies and practice solutions that are reshaping the field of nuclear cardiology. Through proprietary PET imaging systems, services and solutions, Positron enables healthcare providers to more accurately diagnose disease and improve patient outcomes, while practicing cost effective medicine. Positron has made continues their strong commitment to excellence and advancing cardiac imaging solutions.Positron's unique products, market position and approach in facilitating the adoption of cardiac PET to customers are substantial advantages to the growth of nuclear cardiology and Positron.  Positron is redefining the industry. 

More information about Positron is available at (317) 576-0183 or www.positron.com.

Forward Looking Statements:  Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance. These statements may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Positron assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.  Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as “Risk Factors” in our filings with the Securities and Exchange Commission.

 

Print this page

06
Sep

POSITRON ANNOUNCES SALE OF ATTRIUS PET SCANNER

 

Niagara Falls, NY –September 5, 2018 – Positron Corporation (OTC:POSC)(the “Company”), a nuclear medicine healthcare company, is pleased to announce the sale of its Attrius PET scanner to a prominent cardiology practice in the US as they expand their services to include cardiac PET imaging

 

Positron’s President, Adel Abdullah stated, “its sale is significant as representation of the growing demand for cardiac PET and further proof of the value proposition Positron offers in meeting such demand”.

 

“We see demand for PET imaging continuing to accelerate further increasing the need for radiopharmaceuticals and imaging technology.  We believe that Positron’s Attrius PET scanner, clinical services and ability to provide innovative business structures is a perfect solution for all groups seeking to add cardiac PET to their practice”.

 

“Positron as a company offers the only dedicated PET system optimized of cardiac imaging with operations that are very efficient and effective to best serve our customers.  We are able to customize the financial structure, installation, training and continued services to meet the needs of our customers. I am pleased to add that with this customer we delivered ahead of schedule with only 30 days lead time. These are exciting times with much more to follow”.         

 

About Positron: Positron Corporation is a nuclear medicine healthcare company providing innovative PET technologies and practice solutions that are reshaping the field of nuclear cardiology. Through proprietary PET imaging systems, services and solutions, Positron enables healthcare providers to more accurately diagnose disease and improve patient outcomes, while practicing cost effective medicine. Positron has made continues their strong commitment to excellence and advancing cardiac imaging solutions. Positron's unique products, market position and approach in facilitating the adoption of cardiac PET to customers are substantial advantages to the growth of nuclear cardiology and Positron.  Positron is redefining the industry. 

More information about Positron is available at (317) 576-0183 or www.positron.com.

Forward Looking Statements:  Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance. These statements may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Positron assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.  Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as “Risk Factors” in our filings with the Securities and Exchange Commission.

 

Print this page

03
Oct

What Patients Need to Know about PET Scans

Heart disease is a danger like no other, meaning proper diagnosis is of paramount importance. PET scans have been, and continue to be, the best way to get such a diagnosis.

 

Full Text

Print this page

13
Nov

Florbetapir-PET scans show that midlife adults with two or more vascular risk factors are significantly more likely to have greater levels of amyloid deposits in their brains later in life than peers with no such risk factors, according to a study published April 11 in the Journal of the American Medical Association.

 

Full Text

Print this page

13
Nov

GE Healthcare and Lantheus Medical Imaging have launched a second phase III clinical trial for Lantheus' flurpiridaz F-18 investigational PET radiopharmaceutical.

Full Text

Print this page

13
Nov

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the American Society of Nuclear Cardiology (ASNC) submitted a letter to BlueCross BlueShield (BCBS) of Tennessee urging an expansion of cardiac PET coverage.

 

Full Text

Print this page